Posts By: Action Radiotherapy

St. Jude trial identifies a medulloblastoma subset that requires less aggressive therapy

St. Jude Children’s Research Hospital researchers have identified a subtype of the brain tumour medulloblastoma that is associated with improved survival of infants treated with less aggressive, risk-adapted therapy. The report appears today in the journal Lancet Oncology and sets the stage for screening medulloblastoma patients to identify those with the subtype. EurekAlert

‘Proton therapy killed tumour in 70% of liver cancer patients’

Researchers from Samsung Medical Centre have published a study that showed proton therapy to be an effective and safe treatment for liver cancer. According to the research team, almost all patients saw notable improvement with proton therapy administered as an alternative to local cauterisation treatments such as surgery or high-frequency heat therapy. The results were… Read more »

Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials

The use of external beam radiation therapy in the treatment of hepatocellular carcinoma, which was rarely performed due to liver toxicity with a previous technique, has increased. Palliation of portal vein thrombosis, supplementation for insufficient trans-arterial chemoembolisation, and provision of new curative opportunities using stereotactic body radiotherapy are the potential indications for use of external… Read more »

Mobile CT lines up for adaptive proton planning

The Centre for Proton Therapy at Orlando Health UF Health Cancer Centre has successfully installed a mobile CT system for patient localisation and set-up in its compact proton therapy vault. The research team has now described the commissioning process and the dosimetric implications of adaptive planning with the mobile system. Physics World

Combination controversies: checkpoint inhibition alone or in combination for the treatment of melanoma?

The immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab have dramatically improved outcomes for patients with metastatic melanoma; however, not all patients benefit from monotherapy with these agents. To address this issue, complementary combinations of immunotherapy are increasingly being explored as a strategy to improve outcomes, including checkpoint inhibition plus radiotherapy. Cancer Network

UTA researcher patents ‘roach motel’ for cancer

The University of Texas at Arlington has successfully patented in Europe an implantable medical device that attracts and kills circulating cancer cells that was invented by a faculty member. This cancer trap can be used for early diagnosis and treatment of metastasised cancer. This method is effective for both diagnosing and treating metastasis cancer and… Read more »